107 related articles for article (PubMed ID: 11367574)
1. Characteristics of the immunosuppression induced by cutaneous photodynamic therapy: persistence, antigen specificity and cell type involved.
Musser DA; Oseroff AR
Photochem Photobiol; 2001 May; 73(5):518-24. PubMed ID: 11367574
[TBL] [Abstract][Full Text] [Related]
2. IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response.
Gollnick SO; Musser DA; Oseroff AR; Vaughan L; Owczarczak B; Henderson BW
Photochem Photobiol; 2001 Dec; 74(6):811-6. PubMed ID: 11783937
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of a monoclonal antibody to cis-urocanic acid on the suppression of delayed and contact hypersensitivity following ultraviolet irradiation.
Moodycliffe AM; Bucana CD; Kripke ML; Norval M; Ullrich SE
J Immunol; 1996 Oct; 157(7):2891-9. PubMed ID: 8816394
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
5. Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages.
Lynch DH; Haddad S; King VJ; Ott MJ; Straight RC; Jolles CJ
Photochem Photobiol; 1989 Apr; 49(4):453-8. PubMed ID: 2727085
[TBL] [Abstract][Full Text] [Related]
6. Photofrin
Baran TM
Lasers Surg Med; 2018 Jul; 50(5):476-482. PubMed ID: 29214668
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model.
Orenstein A; Kostenich G; Roitman L; Shechtman Y; Kopolovic Y; Ehrenberg B; Malik Z
Br J Cancer; 1996 Apr; 73(8):937-44. PubMed ID: 8611429
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy and anti-tumor immunity.
Gollnick SO; Owczarczak B; Maier P
Lasers Surg Med; 2006 Jun; 38(5):509-15. PubMed ID: 16788921
[TBL] [Abstract][Full Text] [Related]
10. The anatomic site of photodynamic therapy is a determinant for immunosuppression in a murine model.
Musser DA; Camacho SH; Manderscheid PA; Oseroff AR
Photochem Photobiol; 1999 Feb; 69(2):222-5. PubMed ID: 10048313
[TBL] [Abstract][Full Text] [Related]
11. Correlation of anterior chamber-associated immune deviation with suppression of corneal epithelial rejection in mice.
Yao YF; Inoue Y; Miyazaki D; Hara Y; Shimomura Y; Tano Y; Ohashi Y
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):292-300. PubMed ID: 9040461
[TBL] [Abstract][Full Text] [Related]
12. Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells.
Qian J; Hashimoto T; Fujiwara H; Hamaoka T
J Immunol; 1985 Jun; 134(6):3656-61. PubMed ID: 2580893
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-activatable imaging probe reveals enhanced neutrophil elastase activity in tumors following photodynamic therapy.
Mitra S; Modi KD; Foster TH
J Biomed Opt; 2013 Oct; 18(10):101314. PubMed ID: 23897439
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of photodynamic therapy for lung cancers.
Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Maehara S; Imai K; Shima K; Ohira T; Kato H; Ikeda N
Lasers Surg Med; 2011 Sep; 43(7):591-9. PubMed ID: 22057486
[TBL] [Abstract][Full Text] [Related]
15. Studies on the induction of tolerance to alloantigens. III. Induction of antibodies directed against alloantigen-specific delayed-type hypersensitivity T cells by a single injection of allogeneic lymphocytes via portal venous route.
Sato S; Qian JH; Kokudo S; Ikegami R; Suda T; Hamaoka T; Fujiwara H
J Immunol; 1988 Feb; 140(3):717-22. PubMed ID: 2448373
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice.
Anderson CY; Freye K; Tubesing KA; Li YS; Kenney ME; Mukhtar H; Elmets CA
Photochem Photobiol; 1998 Mar; 67(3):332-6. PubMed ID: 9523532
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naive recipients.
Yusuf N; Katiyar SK; Elmets CA
Photochem Photobiol; 2008; 84(2):366-70. PubMed ID: 18208456
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous delayed type hypersensitivity in SCID mice adoptively transferred with lymphocytes is B cell independent and H-2 restricted.
Taube M; Carlsten H
Scand J Immunol; 1997 May; 45(5):515-20. PubMed ID: 9160096
[TBL] [Abstract][Full Text] [Related]
19. Experimental studies of immunotoxicity of a photosensitizing agent (Photofrin II) in mice.
Bianchi R; Giampietri A; Campanile F; Fioretti MC; Puccetti P
J Chemother; 1992 Oct; 4(5):290-6. PubMed ID: 1479418
[TBL] [Abstract][Full Text] [Related]
20. Modulation of delayed type hypersensitivity in mice treated with photoproducts of various photosensitizers used in photodynamic therapy.
Kyagova AA; Kozir LA; Mansurova GV; Zorin VP; Bezdetnaya LN; Guillemin F; Potapenko AY
Russ J Immunol; 2002 Dec; 7(4):327-34. PubMed ID: 12687244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
